Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Traci, Southwell"'
Autor:
Zain M. Hannan, Kim A. Reiss, Natallia Izgur, Ursina R. Teitelbaum, Susan M. Domchek, Robert H. Vonderheide, Charles Schneider, Thomas B. Karasic, Katherine L. Nathanson, Gregory L. Beatty, Rosemarie Mick, Rashmi Tondon, Stacy Cowden, Mark H. O'Hara, Janae Romeo, Traci Southwell, Max M. Wattenberg
Publikováno v:
Journal of Clinical Oncology. 39:2497-2505
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f04f815e04ccf12910bb0a391cc45f96
https://doi.org/10.1200/jco.21.00003
https://doi.org/10.1200/jco.21.00003
Autor:
Kim A, Reiss, Rosemarie, Mick, Mark H, O'Hara, Ursina, Teitelbaum, Thomas B, Karasic, Charles, Schneider, Stacy, Cowden, Traci, Southwell, Janae, Romeo, Natallia, Izgur, Zain M, Hannan, Rashmi, Tondon, Katherine, Nathanson, Robert H, Vonderheide, Max M, Wattenberg, Gregory, Beatty, Susan M, Domchek
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(22)
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germlineEligible patients had advanced PC; germline (g) or somatic (s) PVs inOf 46 enrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5505b56c3409d8d72a5acf4a4c07625a
https://pubmed.ncbi.nlm.nih.gov/33970687
https://pubmed.ncbi.nlm.nih.gov/33970687
Autor:
Renée de Leeuw, Carol L. Jones, Steven Wolf, Traci Southwell, Susan Halabi, Praneet Kang, Susan F. Slovin, Ana M. Molina, Escarleth Fernandez, William Kevin Kelly, Karen E. Knudsen, Celina Fernandez, Mark D. Fleming
Publikováno v:
Journal of Clinical Oncology. 38:84-84
84 Background: Loss of retinoblastoma tumor suppressor (RB) function has been shown to lead to CRPC and is strongly associated with poor outcome. RB functions as a transcriptional repressor; as such, loss of RB causes de-repression of pro-tumorigenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12c76a28899526bd43761e6aafa5ee67
https://doi.org/10.1200/jco.2020.38.6_suppl.84
https://doi.org/10.1200/jco.2020.38.6_suppl.84
Autor:
Jean H. Hoffman-Censits, David Smith, Karen A. Autio, Renée de Leeuw, Christine Hubert, Jahan Aghalar, Gurkamal Chatta, Traci Southwell, Susan F. Slovin, James Luke Godwin, Benjamin E. Leiby, Howard I. Scher, Karen E. Knudsen, William Kevin Kelly, Wassim Abida, Rohit Bose
Publikováno v:
Journal of Clinical Oncology. 36:TPS384-TPS384
TPS384 Background: Current data suggests RB function is often attenuated in tumors through hyperphosphorylation; thus, RB activity can be “re-awakened” in RB+ tumors by suppressing key kinases that phosphorylate RB (CDK4/6). Recent findings ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c67b84a67c9c0e44451b18d53ff1c657
https://doi.org/10.1200/jco.2018.36.6_suppl.tps384
https://doi.org/10.1200/jco.2018.36.6_suppl.tps384
Autor:
Christine Hubert, A. Oliver Sartor, James Luke Godwin, Karen E. Knudsen, Benjamin E. Leiby, Jean H. Hoffman-Censits, William Kevin Kelly, Guru Sonpavde, Matthew J. Schiewer, Akash Patnaik, Traci Southwell, Robert B. Den, Eddy S. Yang
Publikováno v:
Journal of Clinical Oncology. 36:TPS385-TPS385
TPS385 Background: PARP1 is a key regulator of the transition to lethal castrate resistant prostate cancer (CRPC); niraparib is a potent and selective PARP-1 and PARP-2 inhibitor that has shown single agent clinical activity in CRPC. Radium-223 is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99fe1e3c1c861f82e83193776dc375c5
https://doi.org/10.1200/jco.2018.36.6_suppl.tps385
https://doi.org/10.1200/jco.2018.36.6_suppl.tps385